The aim of the present study is to identify factors (such as symptom patterns and symptom scores) that influence the response to treatment with pantoprazole using different evaluation methods (e.g., ReQuest™ questionnaire, patient and investigator assessment). Pantoprazole will be administered once daily in the morning at one dose level. The study duration consists of a treatment period of 8 weeks. The study will provide further data on safety and tolerability of pantoprazole.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
2,000
Pantoprazole 40 mg o.d.
Response to treatment with pantoprazole at week 8, as measured by the questionnaire ReQuest™
Time frame: 8 weeks
Response to treatment with pantoprazole at week 4, as measured by the questionnaire ReQuest™
Time frame: 4 and 8 weeks
Investigator assessment
Time frame: 4 and 8 weeks
Safety and efficacy
Time frame: 4 and 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Altana Pharma/Nycomed
Buenos Aires, Argentina
Altana Pharma/Nycomed
Buenos Aires, Argentina
Altana Pharma/Nycomed
Buenos Aires, Argentina
Altana Pharma/Nycomed
La Plata, Argentina
Altana Pharma/Nycomed
Bedford Park SA, Australia
Altana Pharma/Nycomed
Bondi Junction, Australia
Altana Pharma/Nycomed
Fitzroy, Australia
Altana Pharma/Nycomed
Footscray, Australia
Altana Pharma/Nycomed
Fremantle, WA, Australia
Altana Pharma/Nycomed
Kippa_ring, Australia
...and 176 more locations